Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (guidelines for the specialists on internal medicine, 2nd version)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Approved by XVI Congress of the Scientific Society of Gastroenterologists of Russia and XI National Congress of Internal Medicine on November 25, 2016.

全文:

受限制的访问

参考

  1. Голованова Е.В., Лазебник Л.Б. Обзор международных и отечественных клинических рекомендаций по диагностике и лечению неалкогольной жировой болезни печени. Эксперим. клин. гастроэнтер. 2016; 135(11):76-83. [Golovanov Ye.V., Lazebnik L.B. Review of international and national clinical guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. Experim. Clin. Gstroenter. 2016;135(11):76-83 (in Russ.)]
  2. Голованова Е.В., Винницкая Е.В., Шапошникова Н.А., Петраков А.В, Мелькина Е.С. Эффективность нового растительного гепатопротектора Ропрен в терапии больных с неалкогольным стеатогепатитом. Эксперим. клин. гастроэнтер. 2010;7:97-102. [Golovanov Ye.V., Vinnitskaya Ye.V., Shaposhnikova N.A., Petrakov A.V., Melkina Ye.C. Effectiveness of a new herbal hepatoprotective Ropren in the treatment of patients with nonalcoholic steatohepatitis. Experim. Clin. Gstroenter. 2010;7:97-102 (in Russ.)]
  3. Голованова Е.В., Ковязина И.О., Шапошникова Н.А. Эссенциальные фосфолипиды в терапии неалкогольных стеатогепатитов. Consilium Medicum. 2007;7:23-28. [Golovanov Ye.V., Kovyazina I.O., Shaposhnikova N.A. Essential phospholipids in the treatment of non-alcoholic steatohepatitis. Consilium Medicum. 2007;7:23-28 (in Russ.)]
  4. Грюнграйфф К., Ламберт-Бауманн Й. Эффективность гранул L-орнитинЩ-аспартата при лечении хронических заболеваний печени. Сучасна гастро-ентерологія. 2008;2:59-67. [Grungreiff K., Lambert-Baumann J. The effectiveness of the granules L-ornithine-L-aspartate in the treatment of chronic liver diseases. Suchasna gastroenterol. 2008;2:59-67]
  5. Ермолов С.Ю., Шабров А.В., Ермолова Т.В. и др. Новые подходы к диагностике и коррекции портопеченочной гемодинамики. Эксперим. клин. гастроэнтер. 2007;4:13-16. [Yermolov S.Yu., Shabrov A.V., Yermolova T.V. et al. New approaches to diagnostics and correction portorecanati hemodynamics. Experim. Clin. Gstroenter. 2007;4:13-16 (in Russ.)]
  6. Ермолова Т.В., Яковлева Д.М. Эффективность применения L-орнитинаЩ-аспартата у больных стеатогепатитом. Современная гастроэнтерология и гепатология. 2012;1:22-6. [Yermolova T.V., Yakovlev D.M. The efficacy of L-ornithine-L-aspartate in patients with steatohepatitis. Modern Gastroenterol. Hepatol. 2012;1:22-6 (in Russ.)]
  7. Ефремов Л.И., Лазебник Л.Б., Конев Ю.В. Чревоугодие, ожирение и метаболический синдром в контексте «геми смертных грехов». Эксперим. клин. гастроэнтер. 2013;4:56-61. [Yefremov L.I., Lazebnik L.B., Konev Yu.V. Gluttony, obesity and metabolic syndrome in the context of the «seven deadly sins». Experim. Clin. Gstroenter. 2013;4:56-61 (in Russ.)]
  8. Звенигородская Л.А., Конев Ю.В., Ефремов Л.И. Эволюция представлений о метаболическом синдроме. Эксперим. клин. гастроэнтер. 2011;7:4-8. [Zvenigorodskaya L.A., Konev Yu.V., Yefremov L.I. The evolution of ideas about metabolic syndrome. Experim. Clin. Gstroenter. 2011;7:4-8 (in Russ.)]
  9. Звенигородская Л.А., Мельникова Н.В., Черкашова Е.А., Самсонова Н.Г. Гиполипидемическая терапия у больных с неалкогольной жировой болезнью печени: место гепатопротекторов. Методические рекомендации ДЗ г. Москвы. Москва, 2011. 20 с. [Zvenigorodskaya L.A., Melnikova N.V., Cherkashova Ye.A., Samsonova N.G. Lipid-lowering therapy in patients with nonalcoholic fatty liver disease: hepatic. Guidelines of DZ of Moscow. Moscow, 2011. 20 p. (in Russ.)]
  10. Ивашкин В.Т., Маевская М.В., Широкова Е.Н., Морозова М.А. Опыт применения препарата Эслидин® у пациентов с неалкогольной жировой болезнью печени в практике врача амбулаторного звена (Global Observation of Liver Disease treatment with Eslidin®, «GOLD»). РМЖ. 2015;21:1272-77
  11. Ильницкий А.Н., Максимов В.А., Каримова И.М., Позднякова Н.М. Антивозрастная медицина: вопросы гепатологии (пособие для врачей). ФГБОУ ДПО ИПК ФМБА России, НОГР. М., 2016. [Ilnitsky A.N., Maksimov V.A., Karimova I.M., Pozdnyakova N.M. Anti-aging medicine: issues of hepatology (manual for doctors). Moscow, 2016(in Russ.)]
  12. Лазебник Л.Б., Звенигородская Л.А. Метаболический синдром и органы пищеварения. М.: Анахарсис, 2009. 184 с. [Lazebnik L.B., Zvenigorodskaya L.A. Metabolic syndrome and digestive organs. M.: Anacharsis, 2009. 184 p. (in Russ.)]
  13. Лазебник Л.Б., Конев Ю.В. Микробиота толстой кишки и составляющие метаболического синдрома. Эксперим. клин. гастроэнтер. 2014;5:30-9. [Lazebnik L.B., Konev Yu.V. Microbiota of the large intestine and components of the metabolic syndrome. Experim. Clin. Gstroenter. 2014;5:30-9 (in Russ.)]
  14. Минушкин О.Н. (сост.). Лаеннек в клинической практике. Учебно-методические рекомендации для терапевтов, гастроэнтерологов, курсантов цикла усовершенствования. 2-е изд. Кафедра терапии и гастроэнтерологии ФГБУ ДПО ЦГМА УД Президента РФ. М., 2015. [Minushkin O.N. (ed.). Laennec in clinical practice. Teaching guidelines for therapists, gastroenterologists, cadets of the continuous improvement cycle. 2nd edition. Moscow, 2015 (in Russ.)]
  15. Надинская М.Ю. Гепа-Мерц: биохимические свойства и клинические эффекты. М., 2008. 87 с. [Nadinskaya M.Yu. Hepa-Merz: biochemical properties and clinical effects. Moscow, 2008. 87 p. (in Russ.)]
  16. Осипенко М.Ф., Редькина А.В., Бикбулатова Е.А. и др. Оценка L-орнитин-L-аспартата (Гепа-Мерц) в комплексном лечении неалкогольного стеатогепатита. Гастроэнтерология. Приложение к журналу Consilium Medicum. 2010;1:35-8. [Osipenko M.F., Red'kin A.V., Bikbulatova Ye.A. et al. Assessing L-ornithine-L-aspartate (Hepa-Merz) in treatment of nonalcoholic steatohepatitis. Gastroenterology. Supplement to Consilium Medicum. 2010;1:35-8 (in Russ.)]
  17. Селиверстов П.В., Радченко В.Г. Неалкогольная жировая болезнь печени, новые возможности терапии. Медицинский альманах. 2014;1:38-40. [Seliverstov P.V., Radchenko V.G. Non-alcoholic fatty liver disease, new therapeutic options. Medical almanac. 2014;1:38-40 (in Russ.)]
  18. Чеснокова Л.В. Клинико-патогенетическое значение неалкогольной жировой болезни печени в формировании высокого сердечно-сосудистого риска у больных с метаболическим синдромом. Возможности коррекции. Дисс.. д-ра мед. наук. 2015. [Chesnokova L.V. Clinical and pathogenetic significance of nonalcoholic fatty liver disease in the formation of high cardiovascular risk in patients with metabolic syndrome. Possibilities of correction. Dissertation for the degree of doctor of medical sciences. 2015 (in Russ.)]
  19. Bachar G.N., Dicker D., Kornowski R., Atar E. Epicardial adipose tissue as a predictor of coronary artery disease in asymptomatic subjects. Am. J. Cardiol. 2012;110(4):534-8.
  20. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., Semenkovich C.F., Gordon J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA. 2004;101(44):15718-23.
  21. Baff y G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. Hepatol. 2009;51(1):212-23.
  22. Bellentani S. Immunomodulating and antiapoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur. J. Gastroenterol. Hepatol. 2005;17:137-40.
  23. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006;3:318-28.
  24. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., Ponti V., Pagano G., Ferrannini E., Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005,48:634-42.
  25. Byrne C.D., Targher G. Review. NAFLD: A multisystem disease. J. Hepatol. 2015;62:S47-S64.
  26. Calori G., Lattuada G., Ragogna F., Garancini M.P., Crosignani P., Villa M., Bosi E., Ruotolo G., Piemonti L., Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011;54:145-52.
  27. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012;107:81 1-26.
  28. Chang C.Y., Argo C.K., Al-Osaimi A.M., Caldwell S.H. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 2006;40 (Suppl. 1):S51-S60.
  29. Chang Y., Ryu S., Sung E., Woo H.Y., Cho S.I., Yoo S.H., Ahn H.Y., Choi N.K. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut. 2009,58:1419-25.
  30. Chen M. F., Li R. C., Chen C. H., Gao X. C. Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(6):718-9, 722.
  31. Dajani et al. EPL in the management of primary NAFLD and NAFLD associated with comorbid disease. Hepatol. Int. 2013;7 (Suppl. 1):S108.
  32. Dam-Larsen S., Becker U., Franzmann M. B., Larsen K., Christoffersen P., Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand. J. Gastroenterol. 2009;44(10):1236-43.
  33. DiBaise J.K., Zhang H., Crowell M.D., Krajmalnik-Brown R., Decker G.A., Rittmann B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 2008;83(4):460-9.
  34. Dongiovanni P., Valenti L., Rametta R., Daly A.K., Nobili V., Mozzi E., Leathart J.B., Pietrobattista A., Burt A.D., Maggioni M., Fracanzani A.L., Lattuada E., Zappa M.A., Roviaro G., Marchesini G., Day C.P., Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut. 2010;59:267-73.
  35. Драпкина О.М., Корнеева О.Н. Метаболический синдром и сердечно-сосудистые заболевания у женщин. Насколько велико влияние пола? Сердце. 2011;10(4):224-8. [Drapkina O.M., Korneeva O.N. Metabolic syndrome and cardiovascular disease in women. How great is the influence of female sex? Heart. 2011;10(4):224-8 (in Russ.)]
  36. Драпкина О.М., Зятенкова Е.В. Оценка ремоделирования сердечно-сосудистой системы и толщины эпикардиального жира у пациентов с хронической сердечной недостаточностью и метаболическим синдромом. Тер. архив. 2016;88(2):64-70.
  37. Драпкина О.М., Корнеева О.Н., Ивашкин В.Т. Способ диагностики инсулинорезистентности. Патент 2553943 Российская Федерация; опубликовано 20.06.2015. Бюллетень 2015; 17 [Drapkina O.M., Korneeva O.N., Ivashkin V.T. A method of diagnosing insulin resistance: Patent 2553943 Russian Federation; published on 06.20.201 5. Bulletin 2015;17 (in Russ.)]
  38. Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., Zala J.F., Helbling B., Steuerwald M., Zimmermann A.; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2006;4:1537-43.
  39. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-402.
  40. Ermolova T., Ermolov S., Kolesnikov M. Pharmacological modification of intrahepatic vascular resistance. EASL monothematic conference portal hypertension. Budapest, Hungary, 2009. Poster 19. S85. 90.
  41. Fallo F., Dalla P.A., Sonino N., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 2009;19:646-53.
  42. Farrell G.C., Chitturi S., K.K. Lau G., Sollano J.D.; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary. J. Gastroenterol. Hepatol. 2007;22:775-7.
  43. Fotbolcu H., Yakar T., Duman D., Ozden K., Karaahmet T., Tigen K., Kurtoglu U., Dindar I. Aortic elastic properties in nonalcoholic fatty liver disease. Blood Press Monit. 2010;15:139-45.
  44. Fracanzani A. L., Burdick L., Raselli S., et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009;204:521-5.
  45. Gaiani S., Avogaro A., Bombonato G.C., Bolognesi M., Amor F., Vigili de Kreutzenberg S., Guarneri G., Sacerdoti D. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: Prevalence and relationships with hemodynamic alterations detected with Doppler sonography. J. Ultrasound. 2009;12:1-5.
  46. Garinis G.A., Fruci B., Mazza A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int. J. Obes. dvance online publication. 2010, February 23.
  47. Gastaldelli A., Kozakova M., HDjlund K., Flyvbjerg A., Favuzzi A., Mitrakou A., Balcau S. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49:1537-44.
  48. Goland S., Shimoni S., Zornitzki T., Knobler H., Azoulai O., Lutaty G., Melzer E., Orr A., Caspi A., Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 2006;40:949-55.
  49. Голованова Е.В., Шапошникова Н.А., Мелькина Е.С., Султанов В.С. Гепатопротектор Ропрен в лечении пациентов с неалкогольным стеатогепатитом: проспективное наблюдательное исследование. Эксперим. клин. гастроэнтер. 2016;9(133): 71-6. [Golovanova Y.V., Shaposhnikova N.A., Melkina Ye.S., Soultanov V.S. The hepatoprotector Ropren for the treatment of patients with nonalcoholic steatohepatitis: a prospective observational study. Experim. Clin. Gstroenter. 2016;9(133):71-6 (in Russ.)]
  50. Grungreiff K., Lambert-Baumann J. Die Medizinische Welt. 2001;52:219-26.
  51. Gundermann et al. Essential phospholipids in fatty liver: a scientific update. Clinical and Experimental Gastroenterology. 2016:9:105-17.
  52. Hotamisligil G.S. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.
  53. Iacobellis G., Barbarini G., Letizia C., Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity. 2014;22(2):332-6.
  54. Karabay C.Y., Kocabay G., Kalayci A., Colak Y., Oduncu V., Akgun T., Kalkan S., Guler A., Kirma C. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur. J. Gastroenterol Hepatol. 2014;26:325-31.
  55. Karajamaki A.J., Patsi O.P., Savolainen M., Kesaniemi Y.A., Huikuri H., Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015;10:E0142937
  56. Kircheis G., Nilius R., Held C., Berndt H., Buchner M., Görtelmeyer R., Hendricks R., Krüger B., Kuklinski B., Meister H., Otto H.J., Rink C., Rösch W., Stauch S. Therapeutic efficacy of Lornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatol. 1997;25(6):1351-60.
  57. Kotronen A., Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008;28(1):27-38.
  58. Lee M.K., Park H.J., Jeon W.S., Park S.E., Park C.Y., Lee W.Y., Oh K.W., Park S.W., Rhee E.J. Higher association of coronary artery calcification with nonalcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. Cardiovascular. Diabetology. 2015;14:88.
  59. Lin Y.C., Lo H.M., Chen J.D. Sonographic fatty liver, overweight and ischemic heart disease. World J. Gastroenterol. 2005;11:4838-42.
  60. Loos R.J.F., Savage D.B. Inherited susceptibility to non-alcoholic fatty liver disease. Diabetologia. 2009;52:1000-2.
  61. Mason J.E., Starke R.D., Van Kirk J.E. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev. Cardiol. 2010;13(1):36-41.
  62. Mirbagheri S.A., Rashidi A., Abdi S., Saedi D., Abouzari M. Liver: an alarm for the heart? Liver Int. 2007;27:891-4.
  63. Natale F., Tedesco M.A. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. Eur. J. Echocardiogr. 2009;10:549-55.
  64. Nekam K. Effect of in vivo treatment with OA (Hepamerz) on the activity and expression of SOD in cirrhosis. J. Hepatol. 1991;11:75-81.
  65. Perseghin G., Lattuada G., De Cobelli F., Esposito A., Belloni E., Ntali G., Ragogna F., Canu T., Scifo P., Del Maschio A., Luzi L. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology. 2008;47:51-8.
  66. Jalan R., De Chiara F., Balasubramaniyan V., Andreola F., Khetan V., Malago M., Pinzani M., Mookerjee R.P., Rombouts K. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J. Hepatology. 2016;64:823-33.
  67. Ratziu V., Bellentani S., Cortez-Pinto H., et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010;53:372-384.
  68. Sauer A.J., Moss A.J., McNitt S., Peterson D.R., Zareba W., Robinson J.L, Qi M., Goldenberg I., Hobbs J. B., Ackerman M.J., Benhorin J., Hall W.J., Kaufman E.S., Locati E.H., Napolitano C., Priori S.G., Schwartz P.J., Towbin J.A., Vincent G.M., Zhang L. Long QT syndrome in adults. J. Am. Coll. Cardiol. 2007;49:329-37.
  69. Silvestre O. M., Bacal F., de Souza Ramos D., Andrade J. L., Furtado M., Pugliese V., Belleti E., Andraus W., Carrilho F. J., Carneiro D'Albuquerque L. A., Queiroz Farias A. Impact of the severity of end-stage liver disease in cardiac structure and function. Ann. Hepatol. 2013;12(1):85-91.
  70. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 2008;49:600-7.
  71. Straus S.M., Kors J.A., De Bruin M.L., van der Hooft C.S., Hofman A., Heeringa J., Deckers J.W., Kingma J.H., Sturkenboom M.C., Stricker B.H. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J. Am. Coll. Cardiol. 2006;47:362-7.
  72. Sun L., Lü S.Z. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin. Med. J. 2011;124(6):867-72.
  73. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Zenari L., Cigolini M., Falezza G., Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325-30.
  74. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010;363:1341-50.
  75. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Pichiri I., Mantovani A., Zoppini G., Bonora E., Barbieri E. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 2014;24:663-9.
  76. Targher G., Valbusa F., Bonapace S., Bertolini L., Zenari L., Rodella S., Zoppini G., Mantovani W., Barbieri E., Byrne C.D. Nonalcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One. 2013;8:e57183.
  77. Villanova N., Moscatiello S., Ramilli S., Bugianesi E., Magalotti D., Vanni E., Zoli M., Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-80.
  78. Yilmaz Y. Liver function tests: Association with cardiovascular outcomes. World J. Hepatol. 2010;2(4):143-5.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##